At the time of writing, Abbvie Inc [ABBV] stock is trading at $167.52, down -0.89%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ABBV shares have lost -0.23% over the last week, with a monthly amount drifted -7.41%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 9, April 2024, SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne. In a post published today on Yahoo Finance, From the makers of BOTOX® Cosmetic, two new SkinMedica® acne products help address skin blemishes and can be combined with in-office DiamondGlow®.
From an analyst’s perspective:
Abbvie Inc [NYSE: ABBV] stock has seen the most recent analyst activity on January 29, 2024, when William Blair upgraded its rating to a Outperform. Previously, HSBC Securities downgraded its rating to Hold on December 18, 2023. On December 11, 2023, upgrade upgraded it’s rating to Buy. Deutsche Bank started tracking the stock assigning a Hold rating and suggested a price target of $150 on November 09, 2023. Barclays upgraded its rating to a Overweight and raised its price target to $170 on October 30, 2023. In a note dated September 29, 2023, Raymond James initiated an Outperform rating and provided a target price of $177 on this stock.
For the past year, the stock price of Abbvie Inc fluctuated between $130.96 and $182.89. Currently, Wall Street analysts expect the stock to reach $161.3 within the next 12 months. Abbvie Inc [NYSE: ABBV] shares were valued at $167.52 at the most recent close of the market. An investor can expect a potential drop of -3.71% based on the average ABBV price forecast.
Analyzing the ABBV fundamentals
According to Abbvie Inc [NYSE:ABBV], the company’s sales were 54.32B for trailing twelve months, which represents an -5.42% plunge. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.09%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.4 and Total Capital is 0.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 5.73.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 166.71 points at the first support level, and at 165.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 168.85, and for the 2nd resistance point, it is at 170.18.
Abbvie Inc [ABBV] reported earnings per share of $2.79 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $2.77/share, meaning a difference of $0.02 and a surprise factor of 0.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $2.95 per share as compared to estimates of $2.86 per share, a difference of $0.09 representing a surprise of 3.10%.
Ratios To Look Out For
It is important to note that Abbvie Inc [NYSE:ABBV] has a current ratio of 0.87. As well, the Quick Ratio is 0.76, while the Cash Ratio is 0.34. Considering the valuation of this stock, the price to sales ratio is 5.46, the price to book ratio is 28.56 and price to earnings (TTM) ratio is 61.58.
Transactions by insiders
Recent insider trading involved Donoghoe Nicholas, EVP, CHIEF BUS/STRAT OFFICER, that happened on Mar 20 ’24 when 21082.0 shares were sold. EVP, CHIEF COMMERCIAL OFFICER, Stewart Jeffrey Ryan completed a deal on Mar 18 ’24 to sell 58949.0 shares. Meanwhile, EVP, CHIEF HR OFFICER RICHMOND TIMOTHY J. sold 75680.0 shares on Mar 01 ’24.
